Suloctidil

Suloctidil was a sulfur-containing aminoalcohol that was brought to market in the early 1970s as a vasodilator by Continental Pharma, a Belgian company.[1]^:118–121[2][3]

Suloctidil

Clinical data
ATC code	C04AX19 (WHO)
Identifiers
IUPAC name 1-[4-(isopropylthio)phenyl]-2-(octylamino)propan-1-ol
CAS Number	54767-75-8
PubChem CID	5354
ChEMBL	ChEMBL588119
CompTox Dashboard (EPA)	DTXSID4045638
ECHA InfoCard	100.053.920
Chemical and physical data
Formula	C20H35NOS
Molar mass	337.563 g·mol^−1
(verify)

Continental was bought by Monsanto in 1984, primarily on the promise of sales of suloctidil, which was approved in Europe at the time, but not in the US.[4] However, in 1985 Monsanto halted development and withdrew the drug worldwide following reports of liver toxicity.[5]^:251

References

1. Hladovec J (1989). Antithrombotic Drugs in Thrombosis Models. CRC Press. ISBN 9780849351624.
2. Roncucci R, Roba J, Lambelin G, Ferenczi M, Blaton V, Vandamme D, Peeters H (March 1975). "Potential antilipolytic activity of suloctidil". Die Naturwissenschaften. 62 (3): 141–2. Bibcode:1975NW.....62..141R. doi:10.1007/bf00623284. PMID 1240601.
3. BE granted 739678, Buu-Hoi NP, Lambelin G, Roba J, Jacques G, Gillet C, "1-Subst-phenyl-2-amino-ethanols useful as beta adrenergic agents peripheral vasodilators and hypotensive agents"
4. Staff (5 November 1984). "Monsanto's $150 mil. Life Sciences Research Center". The Pink Sheet.CS1 maint: uses authors parameter (link)
5. "Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals" (PDF). Department of Economic and Social Affairs of the United Nations Secretariat. New York: United Nations. 2005.